DE60037347D1 - Kombinationen enthaltend cGMP-PDE5-hemmer. - Google Patents
Kombinationen enthaltend cGMP-PDE5-hemmer.Info
- Publication number
- DE60037347D1 DE60037347D1 DE60037347T DE60037347T DE60037347D1 DE 60037347 D1 DE60037347 D1 DE 60037347D1 DE 60037347 T DE60037347 T DE 60037347T DE 60037347 T DE60037347 T DE 60037347T DE 60037347 D1 DE60037347 D1 DE 60037347D1
- Authority
- DE
- Germany
- Prior art keywords
- pde5 inhibitor
- combinations containing
- containing cgmp
- cgmp
- pde5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924958.3A GB9924958D0 (en) | 1999-10-21 | 1999-10-21 | Treatment of neuropathy |
| GB9924958 | 1999-10-21 | ||
| GB0021520 | 2000-09-01 | ||
| GB0021520A GB0021520D0 (en) | 2000-09-01 | 2000-09-01 | Treatment of neuropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60037347D1 true DE60037347D1 (de) | 2008-01-17 |
| DE60037347T2 DE60037347T2 (de) | 2008-11-27 |
Family
ID=26244947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60037347T Expired - Fee Related DE60037347T2 (de) | 1999-10-21 | 2000-10-17 | Kombinationen enthaltend cGMP-PDE5-hemmer. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030162782A1 (de) |
| EP (2) | EP1129706A3 (de) |
| JP (2) | JP2001122803A (de) |
| KR (1) | KR20010051181A (de) |
| AT (1) | ATE380049T1 (de) |
| AU (1) | AU781550B2 (de) |
| CA (1) | CA2323839C (de) |
| CO (1) | CO5271711A1 (de) |
| CY (1) | CY1107285T1 (de) |
| DE (1) | DE60037347T2 (de) |
| DK (1) | DK1440709T3 (de) |
| ES (1) | ES2295726T3 (de) |
| HU (1) | HUP0004120A3 (de) |
| IL (2) | IL139073A0 (de) |
| PE (1) | PE20010754A1 (de) |
| PT (1) | PT1440709E (de) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2406947A1 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| FR2809623B1 (fr) * | 2000-06-05 | 2003-09-05 | Sanjuan Benito Arranz | Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| ES2429132T3 (es) | 2001-08-31 | 2013-11-13 | The Rockefeller University | Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| JP4545440B2 (ja) | 2002-01-04 | 2010-09-15 | ヘンリー フォード ヘルス システム | 疾患および損傷の処置のための一酸化窒素ドナー |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| ATE465725T1 (de) * | 2002-12-13 | 2010-05-15 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
| PT1619180E (pt) | 2003-04-23 | 2009-12-29 | Japan Tobacco Inc | Antagonista de casr |
| DE10325813B4 (de) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| DE602005017135D1 (de) | 2004-03-05 | 2009-11-26 | Nycomed Gmbh | Neue verwendung von pde5-hemmern |
| AU2006255028B2 (en) | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| AU2007256633B2 (en) * | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9198924B2 (en) * | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2089034A4 (de) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | Neue verwendungszwecke |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
| KR20100033419A (ko) * | 2007-07-19 | 2010-03-29 | 메타볼렉스, 인코포레이티드 | 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체 |
| MX2010006212A (es) | 2007-12-06 | 2010-08-10 | Intra Cellular Therapies Inc | Compuestos organicos. |
| US8846693B2 (en) * | 2007-12-06 | 2014-09-30 | Intra-Cellular Therapies, Inc. | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones |
| US8927556B2 (en) | 2008-12-06 | 2015-01-06 | Intra-Cellular Therapies, Inc. | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds |
| SG171774A1 (en) * | 2008-12-06 | 2011-07-28 | Intra Cellular Therapies Inc | Organic compounds |
| US8633180B2 (en) | 2008-12-06 | 2014-01-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MA32938B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| JP5710493B2 (ja) | 2008-12-06 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| SG178279A1 (en) | 2009-08-05 | 2012-03-29 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
| EP2483281B1 (de) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituierte tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidinsalze |
| WO2011143607A1 (en) * | 2010-05-14 | 2011-11-17 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
| EP2575817A4 (de) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | Organische verbindungen |
| EP2590657A4 (de) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | Organische verbindungen |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| JP5911854B2 (ja) | 2010-05-31 | 2016-04-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2575765B1 (de) * | 2010-06-07 | 2018-12-05 | Suda Ltd | Mundsprayformulierungen und verfahren zur verabreichung von sildenafil citrat |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| EP2717877B1 (de) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organische verbindungen |
| CN102276511A (zh) * | 2011-06-20 | 2011-12-14 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法 |
| US8449565B2 (en) | 2011-07-21 | 2013-05-28 | Francis Duhay | Approaches to venous occlusion for embolus management |
| US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
| EP3479825B1 (de) | 2013-03-15 | 2021-02-17 | Intra-Cellular Therapies, Inc. | Pde1-inhibitoren zur verwendung bei der behandlung und/oder prävention von zns- oder pns-krankheiten oder störungen |
| TWI659032B (zh) | 2013-03-15 | 2019-05-11 | 美商內胞醫療公司 | 有機化合物及其用途 |
| RU2549459C2 (ru) * | 2013-08-20 | 2015-04-27 | Константин Александрович Корейба | Способ лечения нейропатических трофических язв при синдроме диабетической стопы |
| US9849132B2 (en) | 2014-01-08 | 2017-12-26 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
| DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| EP3177627B1 (de) | 2014-08-07 | 2019-07-24 | Intra-Cellular Therapies, Inc. | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on derivate mit pde1 hemmender wirkung |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2857567T3 (es) | 2014-09-17 | 2021-09-29 | Intra Cellular Therapies Inc | Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC) |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| RU2709786C2 (ru) | 2014-12-06 | 2019-12-20 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
| WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018049200A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
| WO2019152697A1 (en) | 2018-01-31 | 2019-08-08 | Intra-Cellular Therapies, Inc. | Novel uses |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US11111247B2 (en) | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2021026180A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| DE69635135T2 (de) * | 1995-12-28 | 2006-07-06 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolderivate |
| ES2200184T7 (es) * | 1996-07-24 | 2015-02-10 | Warner-Lambert Company Llc | Isobutilgaba y sus derivados para el tratamiento del dolor |
| US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| SI1371647T1 (en) * | 1998-04-20 | 2005-10-31 | Pfizer Inc. | Pyridine-3-carboxylic acid derivatives and their use as intermediates |
| US6331171B1 (en) * | 1998-06-04 | 2001-12-18 | Alcon Laboratories, Inc. | Tip for a liquefracture handpiece |
| GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| AU5995699A (en) * | 1998-10-23 | 2000-05-15 | Bunnage, Mark Edward | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| US6411892B1 (en) * | 2000-07-13 | 2002-06-25 | Global Locate, Inc. | Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris |
| US6453237B1 (en) * | 1999-04-23 | 2002-09-17 | Global Locate, Inc. | Method and apparatus for locating and providing services to mobile devices |
| IL137429A0 (en) * | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
| WO2001026659A1 (de) * | 1999-10-12 | 2001-04-19 | Lareida Juerg | Arzneimittel zur behandlung von neuropathien |
| US7196660B2 (en) * | 2000-11-17 | 2007-03-27 | Global Locate, Inc | Method and system for determining time in a satellite positioning system |
| US6560534B2 (en) * | 2001-06-06 | 2003-05-06 | Global Locate, Inc. | Method and apparatus for distributing satellite tracking information |
-
2000
- 2000-10-16 IL IL13907300A patent/IL139073A0/xx unknown
- 2000-10-16 IL IL152925A patent/IL152925A/en not_active IP Right Cessation
- 2000-10-17 AT AT04010436T patent/ATE380049T1/de not_active IP Right Cessation
- 2000-10-17 DE DE60037347T patent/DE60037347T2/de not_active Expired - Fee Related
- 2000-10-17 EP EP00309129A patent/EP1129706A3/de not_active Withdrawn
- 2000-10-17 ES ES04010436T patent/ES2295726T3/es not_active Expired - Lifetime
- 2000-10-17 DK DK04010436T patent/DK1440709T3/da active
- 2000-10-17 EP EP04010436A patent/EP1440709B1/de not_active Expired - Lifetime
- 2000-10-17 PT PT04010436T patent/PT1440709E/pt unknown
- 2000-10-19 CA CA002323839A patent/CA2323839C/en not_active Expired - Fee Related
- 2000-10-20 AU AU66650/00A patent/AU781550B2/en not_active Withdrawn - After Issue
- 2000-10-20 HU HU0004120A patent/HUP0004120A3/hu unknown
- 2000-10-20 PE PE2000001133A patent/PE20010754A1/es not_active Application Discontinuation
- 2000-10-20 CO CO00080163A patent/CO5271711A1/es not_active Application Discontinuation
- 2000-10-21 KR KR1020000062129A patent/KR20010051181A/ko not_active Ceased
- 2000-10-23 JP JP2000322510A patent/JP2001122803A/ja active Pending
-
2002
- 2002-07-26 US US10/206,615 patent/US20030162782A1/en not_active Abandoned
- 2002-10-10 JP JP2002297617A patent/JP2003119131A/ja active Pending
-
2003
- 2003-12-10 US US10/731,905 patent/US20040122010A1/en not_active Abandoned
-
2008
- 2008-02-18 CY CY20081100193T patent/CY1107285T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU0004120D0 (de) | 2001-01-29 |
| ATE380049T1 (de) | 2007-12-15 |
| JP2001122803A (ja) | 2001-05-08 |
| HUP0004120A2 (hu) | 2002-11-28 |
| HUP0004120A3 (en) | 2003-11-28 |
| IL152925A (en) | 2010-04-15 |
| CO5271711A1 (es) | 2003-04-30 |
| CY1107285T1 (el) | 2012-11-21 |
| EP1129706A3 (de) | 2002-01-02 |
| US20040122010A1 (en) | 2004-06-24 |
| EP1440709A3 (de) | 2004-12-08 |
| PE20010754A1 (es) | 2001-07-18 |
| PT1440709E (pt) | 2008-02-06 |
| AU781550B2 (en) | 2005-05-26 |
| KR20010051181A (ko) | 2001-06-25 |
| EP1129706A2 (de) | 2001-09-05 |
| ES2295726T3 (es) | 2008-04-16 |
| EP1440709A2 (de) | 2004-07-28 |
| CA2323839C (en) | 2008-03-18 |
| CA2323839A1 (en) | 2001-04-21 |
| JP2003119131A (ja) | 2003-04-23 |
| IL139073A0 (en) | 2001-11-25 |
| AU6665000A (en) | 2001-04-26 |
| DE60037347T2 (de) | 2008-11-27 |
| EP1440709B1 (de) | 2007-12-05 |
| DK1440709T3 (da) | 2008-03-17 |
| US20030162782A1 (en) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60037347D1 (de) | Kombinationen enthaltend cGMP-PDE5-hemmer. | |
| MXPA03008968A (es) | Fuente de iluminacion lineal. | |
| GB0206711D0 (en) | HIF Inhibitor | |
| ECSP034600A (es) | Compuestos de lactama | |
| GB2379798B (en) | Light emitting diode and method for manufacturing the same | |
| DE60135387D1 (de) | 7,9 substituierte tetracyclinverbindungen | |
| PL362558A1 (en) | Xylanase variants having altered sensitivity to xylanase inhibitors | |
| IL151299A0 (en) | Aspirin-triggered lipid mediators | |
| MXPA02012494A (es) | Tiazina oxazolidinona. | |
| MXPA04002382A (es) | Combinaciones de herbicidas y antidotos. | |
| BR0102059B1 (pt) | segmento retentor para conjunto turbilhonador. | |
| DK1489082T3 (da) | Mellemprodukter | |
| WO2002014925A3 (en) | Lamp structure, having elliptical reflectors, for uniformly irradiating surfaces of optical fiber and method of use thereof | |
| MY138266A (en) | Treatment of neuropathy | |
| AU2000267392A1 (en) | Improved generator and light emitting wheel having the generator | |
| BR0210678A (pt) | Carbamatos de 2-heterocìclicos-1,2-etanodióis | |
| PT1641447E (pt) | Método de purificação da pravastatina | |
| WO2003014156A3 (en) | NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES | |
| ZA200205460B (en) | A light source. | |
| WO1999066609A3 (de) | Lichtquelle, mit einem ein gas einschliessenden hohlraum | |
| ECSP972265A (es) | Dihidrato de d-olanzapina | |
| ITTO20020158U1 (it) | Luce per veicoli. | |
| RU2001103824A (ru) | Средство для лечения острого мышьяковистого периодонтита | |
| GB0111551D0 (en) | F.R.at source | |
| ES1023775Y (es) | Camara-tunel para desinfeccion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |